Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Laila Ben Salama"'
Autor:
Bart Neyns, Julia Katharina Schwarze, Gil Awada, Laila Ben Salama, Jennifer De Cremer, Lydia Fischbuch, Laura Seynaeve, Stephanie Du Four, Anne-Marie Vanbinst, Alex Michotte, Hendrik Everaert, Anne Rogiers, Peter Theuns, Johnny Duerinck
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Background No treatment demonstrated to improve survival in patients with recurrent glioblastoma (rGB) in a randomized trial. Combining axitinib with the programmed cell death ligand 1 blocking monoclonal antibody avelumab may result in synergistic a
Externí odkaz:
https://doaj.org/article/148c1424e10448fa9ffb5c151ec0bf59
Autor:
Gil Awada, Jennifer De Cremer, Stephanie Du Four, Laila Ben Salama, Bart Neyns, Anne Rogiers, Johnny Duerinck, Lydia Fischbuch
Background: Both PD-L1 and VEGFR are legitimate therapeutic targets in recurrent glioblastoma (rGB). Axitinib, a potent, selective small molecule VEGFR 1-3 inhibitor with single-agent activity in rGB, may synergize with the PD-L1 blocking IgG1 mAb av
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82bdbe1d3ccd3a5ee8f7869aca74a7ef
https://biblio.vub.ac.be/vubir/safety-of-axitinib-plus-avelumab-in-patients-with-recurrent-glioblastoma(acce9ab6-4253-40b0-a58a-f276225b769d).html
https://biblio.vub.ac.be/vubir/safety-of-axitinib-plus-avelumab-in-patients-with-recurrent-glioblastoma(acce9ab6-4253-40b0-a58a-f276225b769d).html
Autor:
Jennifer De Cremer, Anne Rogiers, Gil Awada, Laila Ben Salama, Bart Neyns, Peter Theuns, Julia Katharina Schwarze
Publikováno v:
Journal of Clinical Oncology. 37:97-97
97 Background: Immunotherapy with the CTLA-4 blocking mAb ipilimumab (IPI) has improved the long-term (>3 y) survival of a subpopulation (15-20%) of patients (pts) with metastatic melanoma. Little is known about the psychosocial outcome and the long-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::063e3e5a8f8bf320d30b921162852c3f
https://doi.org/10.1200/jco.2019.37.8_suppl.97
https://doi.org/10.1200/jco.2019.37.8_suppl.97
Autor:
Peter Theuns, Jan L. Bernheim, Laila Ben Salama, Jennifer De Cremer, Bart Neyns, Anne Rogiers, Mark De Ridder
Publikováno v:
Journal of Clinical Oncology. 36:162-162
162 Background: An increasing proportion of advanced melanoma patients (pts), treated with immune checkpoint inhibitors and/or BRAF/MEK-inhibitors, achieve long-term survival. The traumatic experience of melanoma progression, which often involves the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33c6127fee42a63cc1aa667bcc567166
https://doi.org/10.1200/jco.2018.36.7_suppl.162
https://doi.org/10.1200/jco.2018.36.7_suppl.162